In an era where AI-driven drug discovery accelerates candidate generation faster than traditional systems can evaluate them, regulatory velocity becomes a binding constraint Read more at The Business ...

Johnson & Johnson’s Abiomed has sent an urgent medical device correction about a malfunction risk linked to 22 reports of ...

CMS's third drug negotiation cycle under the IRA targets high-expenditure drugs, impacting Medicare Part B and D spending. The list includes drugs for cancer, HIV, and diabetes, with significant ...

Leede Financial analyst Douglas Loe has initiated coverage of Satellos Biosciences with a “Speculative Buy” rating and a ...

Cambridge, Massachusetts, January 14, 2025 - Insilico Medicine (“Insilico”, HKEX:03696), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the ...

Shield’s FDA-approved blood test drives cancer screening growth, pricing power, and cash-flow upside. Click for this GH ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call Transcript January 21, 2026 Johnson & Johnson reports earnings inline with ...

You can't hold back time, but scientists believe they may finally be able to slow down ageing. In a revolutionary new field, they are testing drugs to help people live healthier - for longer.

Baxter (BAX) stock: deep 30–50% valuation discount but limited catalysts as CEO focuses on cuts and deleveraging; learn key risks & upside by 2026—read now.

Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") today provided a business update, including providing preliminary unaudited 2025 revenue estimates and raising full year 2026 and multi-year ...

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

Eli Lilly and Company (NYSE:LLY) reported fourth-quarter financial results on Wednesday. The transcript from the earnings call has been provided below.